Study to Evaluate Efficacy and Tolerability of Micardis®/Micardis® Plus in Patients With Hypertension
Information source: Boehringer Ingelheim
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Hypertension
Intervention: Micardis® (Drug); Micardis® Plus (Drug)
Phase: N/A
Status: Completed
Sponsored by: Boehringer Ingelheim
Summary
Study to evaluate efficacy and tolerability of Micardis®/Micardis® Plus under usual
daily-practice prescribing conditions in hypertensive patients
Clinical Details
Official title: Post-Marketing Surveillance Study Micardis® Plus
Study design: Observational Model: Cohort, Time Perspective: Prospective
Primary outcome: Change in morning blood pressure (office and self-measured)
Secondary outcome: Change in heart rateNumber of patients with adverse drug reactions Assessment of efficacy by investigator on a 5-point scale Assessment of tolerability by investigator on 5-point scale Change in rate of morning complaints
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Males and females for whom a medical antihypertensive therapy is indicated
- Age >= 18 years
Exclusion Criteria:
- Age < 18 years
Locations and Contacts
Additional Information
Starting date: January 2003
Last updated: September 16, 2014
|